Multiple Sclerosis Global Support Network News

"Your trusted source for the latest in MS news and information."

  • MS Info Hub
  • MS News

CMSC 2017 : “Comprehensive Multiple Sclerosis Care: A team Sport” Dr....

https://youtu.be/6-JVbxAiypw Comprehensive Multiple Sclerosis Care: A team Sport" Dr. Boster delivers the 2017 CMSC Kurtzke Memorial Lecture in New Orleans

CMSC 2017: Alemtuzumab Improves RRMS Activity Over 6 Years, Study Says

Remitting-relapsing multiple sclerosis (RRMS) patients with highly active disease (HAD) can find durable treatment from disease activity and lesions over long-term dosage of alemtuzumab,...

CMSC 2017: Jeffrey Cohen, MD, Discusses New MS Criteria

The committee for the International Diagnostic Criteria for Multiple Sclerosis will be releasing its first update of multiple sclerosis (MS) diagnosing standards since 2010,...

CMSC 2017: Single Session of Ball-throwing Exercise Improves Balance Control in...

Patients with relapsing-remitting multiple sclerosis (RRMS) regain part of their balance control after a single training session of ball-throwing exercises, finds a study supported...

CMSC 2017: Teriflunomide for MS Associated With Low Rates of Infection,...

Long-term treatment with teriflunomide for relapsing forms of multiple sclerosis (MS) is associated with a low incidence of low-grade lymphopenias and infections, according to...

CMSC 2017: Q&A: Fred Lublin, MD, on New MS Treatment, Combination...

Fred Lublin, MD, has been a prominent figure in multiple sclerosis (MS) treatment and research for decades. The neurology professor at Mount Sinai Hospital...

CMSC 2017: Review Suggests Certain MS Patient Groups May Discontinue Disease-Modifying...

Older patients with secondary progressive multiple sclerosis (SPMS) as well as older relapsing patients whose MS has been inactive after five years may safely...

CMSC 2017: Cladribine Reduced Annual MS Relapse Rate by 55% to...

Cladribine tablets reduced relapsing multiple sclerosis patients’ annual relapse rate by 55 to 57 percent, depending on the dose, according to clinical trials. EMD Serono,...

CMSC 2017: Alemtuzumab, Ocrelizumab Prove Better Against Relapsing MS in Indirect...

In an indirect comparison of clinical trials for relapsing-remitting multiple sclerosis (RRMS) disease-modifying therapies, researchers found alemtuzumab and ocrelizumab were both more efficient in...

CMSC 2017: Stephen Krieger, MD, Talks Ocrelizumab in RRMS and PPMS...

https://youtu.be/0ExujjC_Jm4 Interest in ocrelizumab has been growing since the antibody's trial data was made available in the fall of 2015. In March, it became the...

Subscribe To Our Newsletter